Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul 1;27(13):3512-3514.
doi: 10.1158/1078-0432.CCR-21-0749. Epub 2021 Apr 23.

How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?

Lawrence D True  1 , Delphine L Chen  2
Affiliations
Comment

How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?

Lawrence D True et al. Clin Cancer Res. .

Abstract

Current techniques for imaging prostate cancer (CT, MRI, and PET agents 18F-fluorodeoxyglucose, 11C-choline, 11C-acetate, and 18F-fluciclovine) are limited in sensitivity and specificity. PSMA PET agent 68Ga-PSMA-11 has recently been approved by the FDA. We comment on the performance of novel PSMA agent 18F-DCFPyL-PET/CT.See related article by Morris et al., p. 3674.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Estimates of the percent of scans that detected cancer (Se) and that are specific for cancer (Sp) for four radiotracers. CT and MRI scans were negative.
See this image and copyright information in PMC

Comment on

References

    1. Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase 3, multicenter study. Clin Cancer Res 2021 - PMC - PubMed
    1. Hadavand MA, Mayer D, Chen W, Wnorowski A, Siddiqui MM. Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer. Curr Opin Oncol. 2020; 32(3): 223–231 - PMC - PubMed
    1. Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1(1):18–28. - PubMed
    1. Tan N, Oyoyo U, Bavadian N, Ferguson N, Mukkamala A, Calais J, Davenport MS. PSMA-targeted Radiotracers versus 18 F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. Radiology 2020;296(1):44–55. - PubMed
    1. Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, Davis BJ. Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. Pract Radiat Oncol 2018;8(1):28–39 - PubMed

Publication types